Highlights
• Quarterly EPS came in below consensus estimates.
• Analyst ratings remain split across buy, hold, and sell.

Quipt Home Medical (NASDAQ:QIPT) announced its quarterly financial results earlier this week. The company reported an earnings per share loss of USD 0.08 for the quarter. This compared with a consensus estimate of a USD 0.03 profit, resulting in a miss of USD 0.11, according to Zacks data.

During the reported period, the company recorded a negative return on equity of 9.78%. Net margin for the quarter stood at negative 4.30%. The results reflect continued pressure on profitability during the period under review.

Analyst Coverage Overview

Quipt Home Medical remains under coverage from several research firms. Weiss Ratings reaffirmed a “sell (e+)” rating in a research note dated October 8. Canaccord Genuity Group adjusted its price target from USD 1.70 to USD 2.30 in an August 19 report and maintained a “hold” rating.

Overall, analyst sentiment remains mixed. One analyst currently rates the stock as a buy, one as a hold, and one as a sell. MarketBeat data shows an average rating of “Hold” with a consensus target price of USD 3.15.

Institutional Activity

Institutional ownership accounted for 42.85% of outstanding shares. Several firms adjusted their positions during recent quarters. Kanen Wealth Management LLC more than doubled its stake in the first quarter. Arrowstreet Capital, Franklin Resources, Russell Investments Group, and Dimensional Fund Advisors also reported increases in their holdings during the third quarter.

Company Overview

Quipt Home Medical Corp. operates through its subsidiaries in the United States. The company provides durable and home medical equipment and supplies. Its offerings include oxygen concentrators, nebulizers, CPAP and BiPAP units, non-invasive ventilation equipment, and related services. The business also engages in the rental of medical equipment across its service regions.

Shares of QIPT closed at USD 3.50, up around 34% on December 16, 2025.